Targeting the genetic weaknesses in a specific type of childhood cancer
EXPLORE AND TARGET THE EPIGENETIC VULNERABILITY OF PAX3-FOXO1-DRIVEN RHABDOMYOSARCOMA
This study is looking at how certain genetic changes help a rare and aggressive childhood cancer called alveolar rhabdomyosarcoma grow, with the hope of finding new ways to treat it and improve outcomes for kids and teens facing this challenge.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. Jude Children's Research Hospital NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-10878910 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain genetic changes contribute to the development of a rare and aggressive childhood cancer called alveolar rhabdomyosarcoma. By investigating the role of specific proteins that drive tumor growth, the researchers aim to identify new treatment strategies that can block these proteins' functions. The study utilizes advanced techniques to analyze the genetic and epigenetic alterations in cancer cells, which may reveal new therapeutic targets. Ultimately, the goal is to improve treatment outcomes for affected children and adolescents.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and adolescents diagnosed with alveolar rhabdomyosarcoma, particularly those with the PAX3-FOXO1 fusion gene.
Not a fit: Patients with other types of cancers or those who do not have the specific genetic markers associated with alveolar rhabdomyosarcoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted therapies for children with alveolar rhabdomyosarcoma, potentially improving survival rates and reducing long-term side effects.
How similar studies have performed: Previous research has shown promise in targeting genetic vulnerabilities in other cancers, suggesting that this approach may also be effective for alveolar rhabdomyosarcoma.
Where this research is happening
Memphis, United States
- St. Jude Children's Research Hospital — Memphis, United States (Active)
Researchers
- Principal investigator: Yang, Jun — St. Jude Children's Research Hospital
- Study coordinator: Yang, Jun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.